Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease
Open accessAbstract
Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Another study vaccinated guinea pigs with two 20 μg doses of a lipid nanoparticle-encapsulated, nucleoside-modified mRNA encoding the EBOV glycoprotein, inducing high antibody titres and protecting the animals from a lethal viral challenge.
“Another study vaccinated guinea pigs with two 20 μg doses of a LNP-encapsulated, nucleoside-modified mRNA encoding the EBOV glycoprotein, inducing high antibody titres and protecting the animals from a lethal viral challenge185.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [185]
Lipid nanoparticle-mRNA vaccines have been tested against other viruses in animal models, including human immunodeficiency virus, Powassan virus, Venezuelan equine encephalitis virus, dengue virus and Ebola virus.
“Furthermore, lipid nanoparticle–mRNA vaccines have been tested against other viruses in animal models, including human immunodeficiency virus28,144,181,190, Powassan virus195, Venezuelan equine encephalitis virus196, dengue virus73 and Ebola virus197.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [197]
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1× · see citing works
“demonstrated in vivo protein expression of exogenously introduced naked mRNA in mouse muscle [5].”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971 · see citing works
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works
Self-citationPetsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 461 · see citing works
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 1× · see citing works
“Thus far, mRNA vaccines targeting influenza A virus [11], rabies virus [12], HIV-1 [13], and Zika virus [6] have been tested in infectious disease animal models and, most recently, in humans [14].”
BackgroundHuttner, A. C., Dayer, J.-A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J. A., Eickmann, M., Finckh, A., Gonçalves, A. R., Hooper, J. W., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00154-1 · Cited by 272 · see citing works
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia
Kennedy, S. B., Bolay, F. K., Kieh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614067 · Cited by 252 · see citing works
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · cited 1× · see citing works
“Thus far, mRNA vaccines targeting influenza A virus [11], rabies virus [12], HIV-1 [13], and Zika virus [6] have been tested in infectious disease animal models and, most recently, in humans [14].”
BackgroundWong, G., Richardson, J. S., Pillet, S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004582 · Cited by 150 · see citing works
Sarwar, U. N., Costner, P. J. M., Enama, M. E., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu511 · Cited by 131 · see citing works
Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
Meyer, M., Garron, T. M., Lubaki, N. M., Mire, C. E., Fenton, K. A., Klages, C., Olinger, G. G., Geisbert, T. W., Collins, P. L., & Bukreyev, A. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81532 · Cited by 74 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579 · see citing works
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507 · see citing works
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512 · see citing works
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299 · see citing works
Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190 · see citing works
Self-citationImmune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153 · see citing works
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · see citing works
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., et al. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.03.003 · Cited by 103 · see citing works
Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
Zhang, M., Sun, J., Li, M., & Jin, X. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.013 · Cited by 90 · see citing works
- Authors
- Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Moderna Therapeutics (United States) (US)
- Valera LLC, Cambridge, Massachusetts
- Corresponding author
- Bukreyev, Alexander
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-21
- Volume
- 217
- Issue
- 3
- Pages
- 451-455
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC5853918
- OpenAlex
- W2777795488
- Cited by
- 178
- References
- 15
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 34 · 2023: 21 · 2022: 36 · 2021: 30 · 2020: 14 · 2019: 10 · 2018: 6
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1R01AI102887-01A1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Keywords
- Ebola virus, mRNA vaccines, envelope glycoprotein, signal peptide, lipid nanoparticles, neutralizing antibodies, post-translational translocation, vaccine immunogenicity, guinea pig challenge, vaccine safety
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Viral, Disease Models, Animal, Drug Carriers, Female, Guinea Pigs, Immunoglobulin G, Liposomes, RNA, Messenger, RNA, Viral, Survival Analysis, Hemorrhagic Fever, Ebola, Ebola Vaccines, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
